Posted on 2/16/21
Bio-Path Holdings Prices of $13.0 Million Public Offering of Common Stock
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a . . .
Posted on 2/16/21
Aravive Announces $21.0 Million Registered Direct Offering
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a . . .
Posted on 2/16/21
CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced preliminary and unaudited revenues for . . .
Posted on 2/16/21
Here's Why You Can't Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna
Johnson & Johnson (NYSE:JNJ) announced late-stage results for its COVID-19 vaccine in late January. The immediate focus was on the vaccine's efficacy, which was markedly lower . . .
Posted on 2/16/21
Why Novavax's COVID Vaccine Results Were So Stellar
Novavax(NASDAQ:NVAX) lags behind bigger players in the COVID-19 vaccine arena such as Pfizer and Moderna. However, in late January the biotech announced very promising results from . . .
Posted on 2/16/21
What's the Outlook for Pfizer Stock?
Pfizer (NYSE:PFE) underperformed the S&P 500 in 2020. And in 2019. And in 2017. And in 2016. You probably noticed I skipped 2018 -- that was . . .
Posted on 2/16/21
Better Coronavirus Stock: Inovio Pharmaceuticals vs. Vaxart
For some small biotechs, the race to develop a COVID-19 vaccine represented an opportunity to secure funding and establish partnerships that could serve as lifelines long . . .
Posted on 2/16/21
CDC Says Reporters Should Be Prioritized For Vaccination; Md. Has Not Yet Done So
The Centers for Disease Control (CDC) recommends that reporters be eligible to receive the COVID-19 vaccine in Phase 1C of distribution but Maryland has not yet . . .
Posted on 2/15/21
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant . . .
Posted on 2/15/21
Bio-Path Holdings Proposed Public Offering of Common Stock
HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a . . .
Posted on 2/15/21
Cassava Sciences Closes of $200 Million Registered Direct Offering
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of . . .
Posted on 2/15/21
HemoShear Therapeutics Raises $40M in Series A
HemoShear Therapeutics, Inc., a Charlottesville, Va.-based clinical stage company developing treatments for rare metabolic disorders, has raised $40m in Series A financing.
Posted on 2/15/21
Maryland’s Average Positive Test Rate Dips Below 5% for First Time Since November
The seven-day average positive test rate in Maryland has dipped below 5% for the first time since the average reached 4.63% on Nov. 7.As of Friday . . .
Posted on 2/13/21
Road to Responsibility Holds Vaccine Clinics for Staff and Residents
Julia Barruzza, residential nurse supervisor for Road to ResponsibilityRoad to Responsibility (RTR), one of the region’s largest and most successful nonprofit organizations supporting individuals with intellectual . . .
Posted on 2/12/21
Enveric Biosciences Closes of $12.8 Million Registered Direct Offering of Common Stock
Enveric Biosciences, Inc. (NASDAQ: ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing on . . .
Posted on 2/12/21
Radius Health Provides Abaloparatide Business Update
BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and continues . . .
Posted on 2/12/21
Infinity Prices of $80 Million Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic . . .
Posted on 2/12/21
SQZ Biotech Prices of Public Offering of Common Stock
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the pricing of its underwritten public . . .
Posted on 2/12/21
Conformis Prices of $85 Million Underwritten Offering of Common Stock
BILLERICA, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has priced an underwritten public offering of 80,952,381 shares of its . . .
Posted on 2/12/21
Caladrius Biosciences Announces $65 Million Registered Direct Offerings
BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed . . .
Posted on 2/12/21
12 Va. Hospitals Rank Among Top in The Nation
Healthgrades released its 2021 list recognizing the top 250 hospitals in the United States, and 12 Virginia hospitals made the cut — with two breaking the . . .
Posted on 2/12/21
Arch Therapeutics Announces $6.9 Million Private Placement
FRAMINGHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH), developer of novel self-assembling wound care and biosurgical devices, today announced that it . . .
Posted on 2/12/21
Could Cassava Sciences Be a Millionaire-Maker Stock?
More than 5.8 million adults in the U.S. live with Alzheimer's disease, and there are more than 487,000 new cases each year. There have been no . . .
Posted on 2/12/21
3 Reasons Pfizer's Failures Could Lead to a Big Acquisition
When Pfizer (NYSE:PFE) included statistics in its recent earnings release showing its pipeline performance over the past five years, there was a not-so-subtle message. The blue-chip . . .
Posted on 2/12/21
Johnson & Johnson's Coronavirus Vaccine Data Isn't as Bad as It First Appears
In this video from Motley Fool Live, recorded on Feb. 1, Fool.com Contributors Brian Orelli and Keith Speights discuss the phase 3 clinical trial results for . . .
